Moderna aro Pfizer para COVID-19 vaccines Phase 3 trials samay HIV-positive volunteers be lobo

August 11, 2020. Jolti te trials loboli wada kura beche tuita(2) key coronavirus vaccine candidates, Moderna-NIAID aro Oxford-AstraZeneca tuh August moina te human trials tuh final stage te jaishe. Etai , Moderna aro Pfizer (kuan khan para German biotech firm BioNTech logot partnered hoikena COVID-19 vaccine bonaishe), tai para trials laga final stage samay
HIV-positive volunteers khan ke be loboli ase koishe. Etai dak te, COVID-19 vaccine nemite human trials samay bemari thaka manuh aro co-morbidities manuh khan ke lowah nai. NIAID-Moderna vaccine laga protocol hesab te, “immunosuppressive or immunodeficient thaka ke olai thishe, etu pithor te human immunodeficiency virus (HIV) bemari thaka manuh ke loishe.

Oxford-AstraZeneca trial laga protocol hesab te, “suspected immunosuppressive nohoile immunodeficient thaka manuh ke lowah nai, koikena Firstpost para khobor koishe. HIV+Aging Research Project, Jeff Taylo para POZ logot koishe ke, “experience nathaka company khan scientific knowledge be najani-kena important vaccine trial nemite tangor incharge deya tuh tax deya manuh nemite besi tangor korcha ase, ami khan para sobo lagibo,” tai koishe. August 5 darik te, Moderna para koishe ke, Phase 3 COVID-19 vaccine trials samay “kuan manuh khan HIV tuh controlled te ase aro kuan khan immunosuppressed” etu manuh khan ke lobo. Company laga planned tuh HIV patients khan logot alak kurikena vaccine test study kuribo. Hoilebi, “hona hesab te community oper te ase” aro jai thaka trial logot melabo, koikena tai aro koishe.